PRODUCTS & RD
Liquid Biopsy (CTC Detect)
- Liquid bodies including Circulating Cell Free DNA(cfDNA)/ Circulating Tumor DNA(ctDNA) 、Circulating Tumor Cells(CTCs) and Extracellular Vesicles (EVs) are isolated from blood sample, can provide the information about genomic mutation ( reverse 、extension 、deletion and point mutation) 、expression level and modification of RNA and protein.
- Development of tumor is result in high-proliferating mutant cells. Due to the increasing evolution of NGS and tumor sequencing, components of tumors, which are shed into the circulation, i.e., circulating tumor cells (CTCs), circulating tumor DNA (ctDNA), or extracellular vesicles, are increasingly being used for monitoring tumor genomes. Analyze of circulating tumor DNA (ctDNA) fragments that are released by tumor cells could be applied to selection in early stage of cancer 、treatment guide for doctors and resistant monitoring.
- Extracellular vesicles (EVs) including Exosomes、Microvesicles and Apoptotic bodies are membrane-encapsulated packages secreted by cells. EVs have been determined that having ability to change the tumor microenvironment, even playing a important role in metastasis. Variant information in EVs could be applied to not only clinical diagnosis but cancer therapy.
- Circulating tumor cells (CTCs) are released by solid tumor or spreading cancer cells that enter to circulatory system.Although CTCs are relatively rare in blood, variant information about genome, RNA and protein in CTCs providing a potentially media for cell pathology, disease progression monitoring and diagnosis means.
Liquid Biopsy in Metagone
Metagone Biotech set up a well-equipped laboratory to devote in cancer research, combining laboratory result with bioinformation system, we found the highly sensitive and specific biomarker (p-DAPK and Meta1).
Association with liquid biopsy, Metagone provides an appropriate method and platform for doctors to set out the suit treatment and drugs.
- Standard biopsy is a traditional way for doctors to diagnose the status of cancer. However, as cancer progression, the previous biopsy sample couldn’t provide the instantly information for treatment.
- Furthermore, there is also possible of surgical incision or needle track leading to the complications through biopsy. Non-invasive biopsy techniques such as magnetic resonance imaging (MRI) and CT scan couldn’t provide complete information of tumor, even lost of small or hidden tumor.
- A liquid biopsy can in principle provide the same genetic information as a tissue biopsy. This approach provide the patients who could not get accessible tissue sample or spread widely to be diagnosed. Liquid biopsy just need 12 days that providing a immediate、safe and non-invasive novel method in clinical analyze.
The global market of liquid biopsy is 410 million dollars in 2015, with the develop of advanced techniques, value of liquid biopsy is expected to $1.94 billion UA dollars in 2020, compound average growth rate of 2015-2020 is 36.2%.Analysts estimate the market potential for liquid biopsy to reach at $28.6 billion by 2026.